Design, Implementation, and Coordination of Malaria Therapeutic Efficacy Studies in Nigeria in 2018
Author:
Olukosi Adeola Yetunde12, Musa Adesola Zaidat1, Ogbulafor Nnenna3, Aina Oluwagbemiga1, Mokuolu Olugbenga4, Oguche Stephen5, Wammanda Robinson6, Okafor Henrietta7, Ekama Sabdat Ozichu1, David Agatha Nkiru1, Happi Christian Tientcha8, Ozor Lynda9, Babatunde Seye9, Ijezie Simon N.3, Uhomoibhi Perpetua E.3, Awolola Samson Taiwo1, Mohammed Audu Bala3, Salako Babatunde Lawal1
Affiliation:
1. Nigerian Institute of Medical Research, Lagos, Nigeria; 2. EKO University of Medical and Health Sciences, Lagos, Nigeria; 3. National Malaria Elimination Program, Abuja, Nigeria; 4. University of Ilorin, Kwara, Nigeria; 5. University of Jos, Plateau, Nigeria; 6. Ahmadu Bello University, Zaria, Nigeria; 7. University of Nigeria Teaching Hospital, Enugu, Nigeria; 8. Redeemer’s University Ede, Osun, Nigeria; 9. WHO, Abuja, Nigeria
Abstract
ABSTRACT.
Prior to 2018, malaria therapeutic efficacy studies (TESs) in Nigeria were implemented separately at different sites, as assigned by the National Malaria Elimination Program (NMEP). In 2018, however, the NMEP engaged the Nigerian Institute of Medical Research to coordinate the 2018 TESs in 3 of 14 sentinel sites with the objective of standardizing their conduct across all three sites: Enugu, Kano, and Plateau states in three of six geopolitical zones. Artemether–lumefantrine and artesunate–amodiaquine, the two first-line drugs for treatment of acute uncomplicated malaria in Nigeria, were tested in both Kano and Plateau states. In Enugu State, however, artemether–lumefantrine and dihydroartemisinin–piperaquine were the test drugs, with dihydroartemisinin–piperaquine being tested for potential inclusion in Nigerian treatment policy. The TES was conducted in 6-month to 8-year-old children and was funded by the Global Fund with additional support from the WHO. A multipartite core team comprised of the NMEP, the WHO, the U.S. Presidential Malaria Initiative, academia, and the Nigerian Institute of Medical Research was set up to oversee the execution of the 2018 TES. This communication reports best practices adopted to guide its coordination, and lessons learned during in the process, including applying developed standard operating procedures, powering the sample size adequately for each site to report independently, training the investigating team for fieldwork, facilitating stratification of decisions, determining efficiencies derived from monitoring and quality assessment, and optimizing logistics. The planning and coordination of the 2018 TES activities is a model of a consultative process for the sustainability of antimalarial resistance surveillance in Nigeria.
Publisher
American Society of Tropical Medicine and Hygiene
Subject
Virology,Infectious Diseases,Parasitology
Reference10 articles.
1. The World Malaria Report 2018,2018 2. World Malaria Report 2020,2020 3. High burden to high impact: a targeted malaria response,2017 4. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children;Oguche,2014
|
|